Paired CSF-Plasma Analyte Signal Contrasts Across Alzheimer's Disease Clinical Stages and MCI-to-Dementia Conversion

Background

Cerebrospinal fluid (CSF) and plasma biomarkers provide complementary information about Alzheimer's disease (AD), but matched analytes are commonly evaluated separately. We investigated whether relative CSF-plasma analyte signals were associated with AD clinical stage and subsequent conversion from mild cognitive impairment (MCI) to AD dementia.